Wellgistics grants 19.8M shares of restricted stock; reports pro forma 2024 revenue of $45.7M

Wellgistics Health, Inc.

Granted 19,764,108 restricted shares under the 2023 Equity Plan, including 9M to CEO vesting on financial metrics for FY2025-2027.
Pro forma consolidated net sales for 2024 were $45.7M, a 33% increase over 2023, assuming recent acquisitions occurred Jan 1, 2023.
Launched EinsteinRx, an AI-driven decision support software integrated into the Wellgistics Hub prescription platform.
Aims to onboard 5,000 pharmacies by mid-2026 and grow active patient base 10x by year-end.
Plans multiple tech-driven acquisitions and predictive care AI for customer service and benefits verification.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.